BTG plc (BTG) Given Consensus Recommendation of “Buy” by Brokerages
BTG plc (LON:BTG) has been assigned an average rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is GBX 779.13 ($10.35).
Several research analysts have weighed in on the stock. J P Morgan Chase & Co restated a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Numis Securities Ltd restated a “buy” rating and set a GBX 900 ($11.96) price objective on shares of BTG plc in a report on Thursday, July 13th. Peel Hunt restated a “hold” rating and set a GBX 680 ($9.04) price objective on shares of BTG plc in a report on Wednesday, September 20th. Deutsche Bank AG restated a “buy” rating and set a GBX 775 ($10.30) price objective on shares of BTG plc in a report on Friday, October 13th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 800 ($10.63) price objective on shares of BTG plc in a report on Wednesday, August 30th.
WARNING: “BTG plc (BTG) Given Consensus Recommendation of “Buy” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/22/btg-plc-btg-given-consensus-recommendation-of-buy-by-brokerages.html.
Shares of BTG plc (LON:BTG) opened at 751.00 on Friday. The firm has a 50-day moving average of GBX 695.12 and a 200 day moving average of GBX 673.01. The firm’s market capitalization is GBX 2.89 billion. BTG plc has a 52 week low of GBX 528.36 and a 52 week high of GBX 764.58.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.